Lacosamide API specifications: reading the impurity profile

What the analytical data package should contain before you commit to a supplier.

What Lacosamide is used for

Lacosamide (CAS 175481-36-4) is a functionalized amino acid that works as a selective slow-inactivation sodium-channel modulator, used as the active ingredient in anticonvulsant formulations, typically for partial-onset seizures. Full specification and sourcing detail is on our Lacosamide API product page.

Enantiomeric purity is the first line to read

Lacosamide’s pharmacological activity is stereospecific, which makes enantiomeric purity — not just overall assay — one of the first things to check on a specification sheet. Ask specifically for the chiral purity method used and the enantiomeric-excess limit, not just a general purity percentage, since a supplier quoting only overall assay may be omitting the test that actually matters for this compound.

Grade and monograph differences that change a filing

As with any API, pharmacopoeial grade (IP/BP/USP/EP) determines which impurity limits and identification tests your filing needs to reference — confirm the grade you need before requesting a quote rather than assuming any grade is interchangeable.

Impurity profile and route consistency

Because Lacosamide’s synthesis involves a chiral center, route changes can shift not just achiral impurities but the enantiomeric ratio itself. A supplier who can’t confirm route stability between batches is a real risk for consistent chiral purity — this is worth asking about directly and in writing.

Why this compound benefits from a real Certificate of Analysis, every batch

A specification sheet tells you what the product should be; only a batch-specific Certificate of Analysis tells you what a given batch actually is — including its actual enantiomeric-excess result, not just a compliance statement. See our buyer’s checklist for what a proper CoA should include, and our GMP compliance checklist for how to verify the certification behind it.

Documentation to request before the first PO

• Batch-specific Certificate of Analysis including chiral purity/enantiomeric-excess result
• Confirmed pharmacopoeial grade matching your filing
• Current GMP certification type and scope
• Route-consistency confirmation and change-notification policy

Sourcing alongside other anticonvulsant or CNS APIs

If you’re also evaluating suppliers for other CNS-active compounds, our Pregabalin API guide covers the same documentation depth for a commonly co-sourced neurology API, including its own regulatory considerations that don’t apply to Lacosamide.

A short checklist before you commit

• Chiral purity method and enantiomeric-excess limit confirmed, not just overall assay
• Grade confirmed against your filing requirements
• Sample CoA reviewed for chiral-purity data specifically
• Route consistency confirmed in writing

Frequently asked questions

Why does chiral purity matter more for Lacosamide than for many other APIs? Its pharmacological activity is stereospecific, so the enantiomeric ratio — not just overall purity — directly affects how the finished formulation performs; a specification sheet showing only overall assay can miss this.

Is Lacosamide sourced as a standard catalogue product or does it typically require custom development? It’s available as a standard, already-manufactured API from our catalogue — see our API Manufacturing page for how standard sourcing works; custom process requirements would fall under a separate CDMO conversation.

What should I ask for if I’m sourcing for a regulated export market? Confirm DMF or equivalent filing status for your specific destination — our plain-English DMF guide explains exactly what that filing covers and why it matters to your own submission timeline.

Is a Certificate of Analysis issued for every batch as standard? Yes — a batch-wise Certificate of Analysis is issued as standard with every despatch.